Clinical Trials on Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated) in Sweden

Total 3 results

Bayer

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma | Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma | Advanced Recurrent Serous Ovarian Cancer | Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

United States, Sweden, Netherlands, United Kingdom, Finland
Cantargia AB

Active, not recruiting

A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR)

Colorectal Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma

Austria, Denmark, Germany, Belgium, Spain, Latvia, Netherlands, Lithuania, Estonia, Sweden, Norway
Region Stockholm

Recruiting

Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or Fully Covered Metal Stents

Bile Duct Cancer | Duodenal Cancer | Pancreatic Cancer Non-resectable | Papillary Carcinoma

Sweden

3

Subscribe